KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$10.49 USD
-0.51 (-4.64%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $10.52 +0.03 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
KalVista Pharmaceuticals, Inc. [KALV]
Reports for Purchase
Showing records 101 - 107 ( 107 total )
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
First HAE Candidate Unveiled; Reiterate Buy - Raising PT to $22
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Spotlight on HAE: Takeaways From Our KOL Discussion
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Force Is Strong with This One; Initiating with Buy - $20 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Force Is Strong with This One; Initiating with Buy - $20 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.